Posted by Michael Wonder on 03 Jun 2022
Gamida Cell completes rolling biologics license application submission to the FDA for omidubicel
2 June 2022 - Omidubicel has orphan drug designation and breakthrough therapy designation.
Gamida Cell today announced completion of the rolling biologics license application submission to the U.S. FDA for omidubicel for the treatment of patients with blood cancers in need of an allogenic haematopoietic stem cell transplant.
